share_log

Piper Sandler Initiates Coverage On Allogene Therapeutics With Overweight Rating, Announces Price Target of $11

Piper Sandler Initiates Coverage On Allogene Therapeutics With Overweight Rating, Announces Price Target of $11

派珀·桑德勒以增持評級開始對Allogene Therapeutics進行報道,宣佈目標股價爲11美元
Benzinga ·  05/31 05:53

Piper Sandler analyst Biren Amin initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Overweight rating and announces Price Target of $11.

派珀·桑德勒分析師比倫·阿明以增持評級啓動了對Allogene Therapeutics(納斯達克股票代碼:ALLO)的報道,並宣佈目標股價爲11美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論